Quantcast
Last updated on April 18, 2014 at 17:24 EDT

Latest CardioFocus Inc. Stories

2014-01-09 08:28:09

Hospital Universitari i Politecnic La Fe in Valencia is First in Country to Use New Technology MARLBOROUGH, Mass., Jan. 9, 2014 /PRNewswire/ -- CardioFocus, Inc., developer of the HeartLight® Endoscopic Ablation System (EAS) for the treatment of atrial fibrillation (AF), announces that its technology is now available in Spain for clinical use. Physicians at Hospital Universitari i Politecnic La Fe in Valencia were the first in the country to offer the innovative catheter ablation...

2013-10-15 08:29:56

Major Achievement Toward U.S. Availability of Single Procedure Treatment for World's Most Common Arrhythmia MARLBOROUGH, Mass., Oct. 15, 2013 /PRNewswire/ -- CardioFocus, Inc., developer of the HeartLight® Endoscopic Ablation System (EAS) for the treatment of atrial fibrillation (AF), today announced that it has concluded enrollment of its U.S. pivotal trial evaluating the HeartLight system, for the treatment of symptomatic paroxysmal AF. The randomized, controlled trial completed...

2013-06-25 08:29:11

First to Prospectively Assess Outcomes of Pulmonary Vein Isolation with Balloon Ablation Catheters in Persistent AF Population MARLBOROUGH, Mass., June 25, 2013 /PRNewswire/ -- CardioFocus, Inc., developer of the HeartLight® Endoscopic Ablation System for the treatment of atrial fibrillation (AF), announces that its HeartLight technology is the focus of a multicenter European clinical study for the treatment of drug-refractory persistent AF. The study, taking place at five centers...

2013-05-07 08:31:53

Scientific Session Presentations Feature Laser Balloon Ablation as Single Procedure Treatment for Atrial Fibrillation MARLBOROUGH, Mass., May 7, 2013 /PRNewswire/ -- CardioFocus, Inc., developer of the HeartLight® Endoscopic Ablation System for the treatment of atrial fibrillation (AF), announces that clinical experiences with its technology will be included as part of the scientific sessions at Heart Rhythm 2013, the Heart Rhythm Society's 34(th) Annual Scientific Sessions, May...

2013-05-01 16:30:20

ALEXANDRIA, Va., May 1, 2013 /PRNewswire/ -- Oxford Finance LLC ("Oxford"), a specialty finance firm that provides senior debt to life sciences and healthcare services companies, today announced the closing of an $11 million round of debt financing for CardioFocus. The credit facility was awarded to CardioFocus from both Oxford and Silicon Valley Bank. Funds will be used to increase the company's available capital to fund growth, while it expands its international commercialization and...

2013-04-16 08:29:17

Names Paul LaViolette as Executive Chairman and Renny Clark as Chief Financial Officer MARLBOROUGH, Mass., April 16, 2013 /PRNewswire/ -- CardioFocus, Inc., developer of the HeartLight® Endoscopic Ablation System for the treatment of atrial fibrillation (AF), announced today that it has expanded its management team. Paul LaViolette, previously Chairman of the Board, has been named Executive Chairman and Renny Clark has been named Chief Financial Officer and Treasurer. They will...

2013-04-10 08:31:53

Presentations Review Findings from Nearly 1,000 Clinical Cases Performed in Germany to Date MARLBOROUGH, Mass., April 10, 2013 /PRNewswire/ -- CardioFocus, Inc., developer of the HeartLight® Endoscopic Ablation System for the treatment of atrial fibrillation (AF), announced today that cardiologists throughout Germany gathered to discuss clinical experiences with the HeartLight System and its role in the treatment of advanced AF. The featured event was held on April 3, in...

2013-01-14 02:30:00

MARLBOROUGH, Mass., Jan. 14, 2013 /PRNewswire/ -- CardioFocus, Inc., developer of the HeartLight® Endoscopic Ablation System for the treatment of atrial fibrillation (AF), announces the U.S. pivotal trial evaluating the safety and efficacy of the HeartLight system is approximately half enrolled. The study, initiated in 2012, is on track to complete enrollment this year. HeartLight is the first catheter ablation system to incorporate an endoscope for direct visualization of the beating...

2013-01-10 08:25:25

MARLBOROUGH, Mass., Jan. 10, 2013 /PRNewswire/ -- CardioFocus, Inc., developer of the HeartLight® Endoscopic Ablation System for the treatment of atrial fibrillation (AF), announces that as of late 2012, more than 1,000 clinical cases have been performed worldwide using the HeartLight technology. The company will be hosting an expert symposium to review the clinical application of HeartLight and key observations made during the first 1,000 cases, which will be held the evening of...

2012-09-06 02:32:00

MARLBOROUGH, Mass., Sept. 6, 2012 /PRNewswire/ -- CardioFocus, Inc., developer of the HeartLight® Endoscopic Ablation System (EAS) for the treatment of atrial fibrillation (AF), announces new data showing pulmonary vein isolation (PVI) with its technology leads to a 99% acute success rate and up to an 82% chronic success rate at 12 months follow-up. In addition, the research indicates the HeartLight laser balloon technology resulted in improved long-term outcomes after a single procedure...